<DOC>
	<DOC>NCT02218879</DOC>
	<brief_summary>The primary objective is to directly estimate brain glutathione concentrations in vivo using H-MRS at 7T before and after initiation of Tecfidera in established multiple sclerosis (MS) patients considering switching therapy or being treatment-naive (first line).</brief_summary>
	<brief_title>Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Male or female adult patients 1860 years of age Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010) Patients naive to MS therapy or patients switching from an FDAapproved MS therapy, including IFNB formulations, Cop1, Teriflunomide, and Fingolimod to BG12 Expanded Disability Status Scale (EDSS) score 0 to 5.5 inclusive Primary progressive multiple sclerosis patients Patients with previous exposure or known allergies to fumarates MS patients switching from natalizumab, cyclophosphamide, or mitoxantrone to BG12 Contraindications for MRI/MRS Known presence of other neurological disorders that may mimic multiple sclerosis Pregnancy or lactation Requirement for chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study History of or currently active primary or secondary immunodeficiency Active infection, or history of or known presence of recurrent or chronic infection (e.g. hepatitis B or C, HIV, syphilis, tuberculosis_ History of progressive multifocal leukoencephalopathy Contraindications to or intolerance of oral or intravenous (IV) corticosteroids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>